ResApp share price surges 11% higher on positive update

The ResApp Health Ltd (ASX:RAP) share price has been on fire on Monday morning. Here's why…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price has started the week on a positive note.

In morning trade the digital health company's shares have surged 11% higher to 24.5 cents.

This leaves the company's shares trading within sight of their 52-week high of 27 cents.

Why is the ResApp share price surging higher?

ResApp's shares have taken off this morning after the market responded positively to the top-line results from its prospective, blinded at-home obstructive sleep apnoea study.

According to the release, ResApp's algorithms, which analyse a person's breathing and snoring sounds recorded using a smartphone placed on a bedside table, were able to accurately identify obstructive sleep apnoea (OSA) when compared to a simultaneous at-home comprehensive sleep study.

The release explains that a total of 308 patients were recruited for the study. However, those with partners and pets in the room were excluded, meaning a total of 238 patients were analysable.

The study endpoints were the algorithms' performance in identifying three severities of OSA. These were mild, moderate, and severe and were compared to an American Academy of Sleep Medicine Type II sleep study performed simultaneously in the patient's home.

The good news for ResApp shareholders is that for all three AHI thresholds, the area under the receiver operating characteristic curve (AUC) was greater than 0.91. This demonstrates that ResApp's algorithms, when used at-home, have an excellent ability to identify mild, moderate, or severe OSA.

Interestingly, in a recent ResMed Inc. (ASX: RMD) presentation, it revealed that research shows that less than 20% of those with OSA have been diagnosed or treated. So there certainly could be a large market opportunity for ResApp if it can successfully diagnose people through a smartphone app.

ResApp's CEO, Tony Keating, was pleased with the results. He said: "We achieved excellent performance previously during our in-laboratory sleep studies and it is great to see the same high levels of performance replicated in our intended use setting, in peoples' homes."

Mr Keating also referenced the same data used by ResMed. Adding: "Nearly one billion people suffer from sleep apnoea and 80% of those with moderate or severe sleep apnoea remain undiagnosed. By delivering a highly scalable, low cost smartphone app for OSA screening we have a huge opportunity to reduce the health and economic impact of undiagnosed OSA. We will now move forward into the regulatory submission and commercialisation phases of this exciting project."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Why Capricorn Metals, Insignia, Perseus Mining, and Qoria shares are storming higher

These shares are having a strong session on Tuesday. But why?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Amaero, AMP, Block, and South32 shares are racing higher today

These shares are starting the week on a positive note. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »